Bill Wexler's Dog Pound Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : Bill Wexler's Dog Pound

REFR 2.030

+0.7%

Oct 29 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Kevin Podsiadlik who wrote (7257)	7/23/2000 10:37:15 AM
From: DanZ	Read Replies (3) of 10293

You're right, Kevin. I can't point you to a URL that shows Pfizer lost money on Viagra during its launch. I can't point you to a URL that shows Microsoft lost money on any of its thousands of new products. I can't point you to a URL that shows Ford or GM lost money on even one of their new vehicles. Actually if I did the research, I might be able to find proof in one of those company's press releases or SEC filings. But what's the point? A reasonable person without an axe to grind and apparent spite for Gum Tech would agree that most companies lose money on new products during their launch and that the mild weather had an adverse effect on sales of Zicam--and also affected all companies that sell cough and cold products. New products are generally judged based on sales growth, gross margins, and expectations for future growth. They aren't judged on whether the company made a profit during the launch. If you would put away your hate stick and be reasonable, you wouldn't get responses from me that you call arguing. To Dale: I don't have all the prices where Wexler recommended shorting the list of stocks in your last post. I took a quick look at some of the prices, and going by memory, most of them are either trading above where he shorted them or near the same price. One's performance in the market should be judged by how much money they make for a certain amount of risk. I don't see the relevance of whether a stock is trading above 30. Obviously it wouldn't be good to short a stock at 10 if it is trading at 29. Oh, but it would be trading below 30! LOL Gosh, I really hate to revive this thread. It's been so nice the last few months not having to deal with the crap that people spew on this thread. Everyone get your last word in and let's shut this thing down again! Here's my last word on GUMM for this thread. If the prophylactic clinical study for Zicam comes back positive, I predict that GUMM will trade over 35 within a week of that news release. I also predict that Gel Tech will have a marketing partnership with a pharmaceutical company before this cold season starts. Last, I predict that GUMM will never reach Wexler's target of $5 (~$50 million market cap). Bye!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next